Major Lp(a)-Lowering Drug Fails To Prevent Heart Attacks In Big Trial
Researchers reported Saturday that the experimental drug pelacarsen, once seen as a potential game-changer for heart disease, failed to prevent heart attacks, strokes or other major cardiovascular events in a large international trial unveiled at the American Heart Association meeting in Chicago.[1]
The five-year randomized study followed 8,350 adults who already had heart disease and were given either pelacarsen or a placebo in addition to standard therapies, including statins, but patients on the drug did no better at avoiding cardiovascular complications despite seeing their lipoprotein(a), or Lp(a), levels drop by about 78 percent.[1] Novartis, which co-developed pelacarsen, acknowledged the trial did not meet its primary endpoint, and detailed results were published simultaneously in the New England Journal of Medicine and NEJM Evidence.[1]
Lp(a) has attracted intense interest in cardiology because about 20 percent of the global population, roughly 1 billion people, are believed to have elevated levels of the particle, which is genetically determined and has been linked in observational studies to higher risks of heart attack and stroke.[1] For years, drugmakers and researchers have pursued therapies that specifically target Lp(a), arguing that cutting it could unlock a new front in cardiovascular prevention beyond cholesterol-lowering statins and newer agents like PCSK9 inhibitors.[1] Pelacarsen, an antisense oligonucleotide designed to block Lp(a) production in the liver, became one of the most closely watched candidates after early-phase trials showed it could slash the lipoprotein by more than 80 percent in some patients with relatively manageable side effects.[1]
The new findings now force scientists to grapple with whether Lp(a) is truly a causal driver of cardiovascular disease or more of a marker that travels with other, harder-to-modify risks, and whether lowering it later in life can undo decades of arterial damage in people who already have heart disease.[1] Cardiologists at the Chicago meeting said the result will likely reshape drug-development plans and may shift research toward starting Lp(a)-lowering earlier, exploring different mechanisms, or focusing more aggressively on traditional risk factors that already have proven outcome benefits.[1]
Because so many people have elevated Lp(a) and no current therapies specifically approved to treat it, the disappointment carries global implications for patients who have pinned hopes on genetic tests and novel drugs to reduce their inherited heart risk.[1] Researchers stressed that the pelacarsen data do not rule out all future Lp(a)-targeted strategies, but they do underscore that dramatically changing a blood biomarker is not enough; any new drug will have to prove that it actually prevents heart attacks and strokes in rigorous outcome trials.[1]
Show source details & analysis (1 source)
📌 Key Facts
- On Saturday, November 7, 2026, researchers reported that pelacarsen failed to reduce heart attacks, strokes or other cardiovascular events despite cutting Lp(a) by about 78% in a 5-year trial.
- The randomized study enrolled 8,350 adults with existing heart disease who received either pelacarsen or placebo on top of standard therapies.
- Results were presented at the American Heart Association meeting in Chicago and published in the New England Journal of Medicine and NEJM Evidence, with Novartis acknowledging the primary endpoint was not met.
- About 20% of the global population—roughly 1 billion people—have elevated lipoprotein(a), making the negative outcome broadly significant for future drug-development and prevention strategies.
📰 Source Timeline (1)
Follow how coverage of this story developed over time